The phrase "allow better characterisation of" is correct and usable in written English.
It can be used when discussing the improvement or enhancement of the description or understanding of a subject or concept.
Example: "The new research methods allow better characterisation of the species' behavior in its natural habitat."
Alternatives: "enable improved description of" or "facilitate enhanced understanding of".
A major strength of our study was the use of multiple birds (10 15) from each of the populations analysed, which allowed better characterisation of the detected variants e.g. provided the opportunity to explore the allele-frequency patterns of InDels.
Furthermore, proteomics used for investigating the proteins involved in tissue repair and destruction may allow for better characterisation of the extent of airway remodelling in each patient (Vignola et al, 2002).
Combining molecular (Refs 31, 52), biophysical (Refs 14, 31, 69, 136, 137), cellular (Refs 93, 114, 138) and animal (Refs 126, 128, 139) studies will allow a better characterisation of the sphingolipids that regulate amyloid oligomerisation/aggregation.
This previous work demonstrated that molecular (or gene) signatures obtained from microarray experiments allow a better characterisation of the pathology than the current clinical scheme based on histopathological classification (Nutt et al, 2003; Freije et al, 2004; Phillips et al, 2006).
The advent of more advanced techniques allows a better characterisation of sandstone surface crusts, commonly present in urban stone decay.
A complementary molecular imaging technique allows for better characterisation of incidental findings from screening procedures, such as solitary lung nodules, dense breast lesions and suspected prostate cancer, thus avoiding unnecessary invasive procedures and biopsies in patients with negative molecular scans [21].
It offers a simultaneous visualisation of all human chromosomes in different pseudocolours, and allows a better characterisation of the rearrangements.
By pooling three T2DM studies we obtained a pooled safety database of 1026 patients, which allowed a better characterisation of the safety profile of canakinumab than was possible in each individual trial [ 24- 27].
Unlike in other studies, the patients who received paclitaxel were not selected at the time of second-line treatment, thus, allowing a better characterisation of the type of patients who could benefit from second-line paclitaxel.
